It takes years after her and finally the results seem to confirm that the day is coming to be able to present it to humanity. The Colombian scientist Manuel Elkin Patarroyo He has assured this Monday at Casa América, where he has been presented as the Príncipe de Viana de la Solidaridad Prize, that his synthetic vaccine against malaria, which will be called 'Colfavac' (Colombian falciparum vaccine), will begin to be tested in humans in June 2012. After these trials, it hopes that it could be ready for 2016.
Patarroyo has said that it has already achieved "a 90 percent effectiveness with the vaccine in monkeys" and that now his team works "in a second line of protection" for the vaccine, where they are having "very good results". He also affirms that, once proven its effectiveness in humans, its production process will be "fast and cheap" -produce each dose will cost less than 15 cents, because the rules to create this type of vaccines, published last March in the specialized magazine 'Chemical Reviews', "they are clear and very well defined".
Your production process will be "fast and cheap": producing each dose will cost less than 15 cents
Of course, recognizes that where they can find more problems will be in the distribution, unless "countries request it", and ensures that your product will follow all legal processes that both the United States drug authorities (FDA, for their acronym in English) as of Europe (EMA).
On the other hand, the scientist and his team are still working on the keys to produce synthetic vaccines against the different known infections. All of them, says the scientist, will carry the prefix 'Col' from Colombia, then the name of the parasite to fight and then the suffix 'vac'. The next disease against which the Patarroyo team will develop synthetic vaccine will be malaria produced by the Plasmodium vivax and against tuberculosis. In addition, it has revealed that various public institutions have shown interest in the Patarroyo team starting to work on a vaccine for dengue and leishmaniasis.
Source: EUROPE PRESS